NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球念珠菌藥物市場:未來前景(2020-2027)

Global Candidiasis Therapeutics Market - 2020-2027

出版商 DataM Intelligence 商品編碼 961508
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
全球念珠菌藥物市場:未來前景(2020-2027) Global Candidiasis Therapeutics Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

念珠菌藥物的全球市場受到以下因素的影響,例如研發活動(R&D)的增加,感染病例的數量增加,免疫力減弱的患者人數的增加以及對各種治療方法的興趣增加。在該支持下,預計未來的擴展趨勢將繼續。另一方面,與替代療法的競爭會阻礙市場的增長。按類型劃分,對生殖器陰道念珠菌病(VVC)的需求有望在未來顯著增長。按地區劃分,北美國家是最大的市場。

本報告分析了念珠菌藥物的全球市場,並按類型,藥物類別和給藥方式分析了市場的基本結構和最新情況,整體市場趨勢的展望(未來8年)。我們正在按路線/分銷渠道和地區,主要市場促銷/限制因素,市場競爭結構,主要公司的概況,業務策略等調查詳細趨勢。

目錄

第1章全球念珠菌藥物市場:分析方法/範圍

第2章全球念珠菌藥物市場:定義和概述

第3章全球念珠菌藥物市場:執行摘要

第4章全球念珠菌藥物市場:市場動態

  • 影響市場的因素
    • 促進因素
    • 抑制因素
    • 市場機會
    • 影響分析

第5章全球念珠菌藥物市場:產業分析

  • 流行病學
  • 管道分析
  • 波特的五力分析
  • 供應鏈分析
  • 臨床試驗
  • 價格分析
  • 監管分析
  • 贖回分析
  • 未滿足的需求

第6章全球念珠菌藥物市場:COVID-19分析

  • 分析Covid-19對市場的影響
    • "新型冠狀病毒之前" /過去的市場情景
    • "新型冠狀病毒" /當前市場情景
    • "新型冠狀病毒之後" /未來市場情景
  • Covid-19流行價格趨勢
  • 供應/供應波動區域
  • 大流行期間與市場有關的政府舉措
  • 製造商的戰略計劃
  • 結論

第7章全球念珠菌藥物市場:按類型

  • 簡介
  • 市場規模分析和同比增長率(YoY):按類型
  • 市場向心力指數:按類型
    • 口腔念珠菌病
    • 陰道念珠菌病
    • 皮膚念珠菌病
    • 侵襲性念珠菌病
    • 全身性念珠菌病

第8章全球念珠菌藥物市場:按藥品類別

  • 簡介
  • 市場規模分析和同比增長率(yoy):按藥物類別
  • 市場向心力指數:按藥品類別
    • Polyene
    • Azole Antifungals
    • Topical azoles
    • Glucan synthesis inhibitors (echinocandins)
    • Antimetabolite
    • Allylamines
    • 其他

第9章全球念珠菌治療市場:按管理途徑

  • 簡介
  • 市場規模分析和同比增長率(YoY):按管理途徑劃分
  • 市場傳入指數:按管理途徑
    • 口服給藥
    • 腸胃外給藥
    • 局部用藥

第10章全球念珠菌藥物市場:通過分銷渠道

  • 簡介
  • 市場規模分析和同比增長率(YoY):按分銷渠道
  • 市場向心力指數:按分銷渠道
    • 醫院藥房
    • 在線藥房
    • 零售藥房
    • 其他

第11章全球念珠菌藥物市場:按地區

  • 簡介
  • 市場規模分析和同比增長率(YoY):按地區
  • 市場向心力指數:按地區
  • 北美
    • 簡介
    • 區域市場的獨特趨勢
    • 市場規模分析和同比增長率(YoY):按類型
    • 市場規模分析和同比增長率(yoy):按藥物類別
    • 市場規模分析和同比增長率(YoY):按管理途徑劃分
    • 市場規模分析和同比增長率(YoY):按分銷渠道
    • 市場規模分析和同比增長率(yoy):按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第12章全球念珠菌藥物市場:競爭形勢

  • 比賽場景
  • 市場定位/份額分析
  • 企業併購分析(併購)

第13章全球念珠菌藥物市場:公司概況

  • Cidara Therapeutics Inc.
    • 公司簡介
    • 產品組合/概述
    • 最新趨勢
    • 財務分析:概述
  • NovaDigm Therapeutics Inc
  • Amplyx Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Biopharmaceuticals
  • Viamet Pharmaceuticals Holdings, LLC
  • Mycovia Pharmaceuticals Inc
  • Novabiotics Limited
  • Bayer AG
  • Biomar Microbial Technologies
  • Merck
  • Scynexis Inc.
  • Pfizer, Inc.
  • 其他公司

第14章全球念珠菌藥物市場:重要考慮因素

第15章關於DataM Intelligence

目錄

Market Overview

The global candidiasis therapeutics Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Candidiasis, also known as thrush is a type of fungal infection which can affect men and women of all age groups. When the infection spreads into the throat, it causes esophagitis. It is also known by several different names such as moniliasis, candidosis, and oidiomycosis. The effects of this infection can be seen on internal, dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush. The market is growing due to the widespread occurrence of this infection, limited efficacious antifungals as well as the lack of reliable treatments. Some of the major drug classes for the treatment of candidiasis include azoles, polyenes and echinocandins.

Market Dynamics

The global candidiasis therapeutics market growth is driven by the rising number of candidiasis infection cases globally, an increase in the susceptible immune-compromised patient pool, and growing awareness towards different treatments for candidiasis infection.

Increasing research and development for candidiasis treatment

The global candidiasis market is expected to grow significantly over the forecast period due to growing research & development for novel medications for the treatment of invasive fungal infections caused by Candida albicans. For instance, in October 2018, some of the researchers at the American Society for Microbiology found a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, hence having a greater potential for use as a pan-antifungal drug.

Rising number of patients with different candidiasis infection

The increasing number of patients affected by candidiasis infection is also one of the major factor driving the growth of the candidiasis treatment market. According to the Center for Disease Control and Prevention (CDC), about 46,000 cases of healthcare-associated invasive candidiasis occur annually, in the United States. The 30-day all-cause (crude) mortality among people with candidemia is around 30%. However, as people who infect from invasive candidiasis commonly have pre-medical disorders, it is ambiguous to determine the proportion of deaths directly attributable to the infection. Hence, this rise in the number of patients has helped in impelling the growth of the overall market.

Availibility of alterate treatments if likely to hinder the market growth

However, easy access to alternative treatment methods such as over-the-counter treatments and side-effects caused by these drugs are expected to hamper the market growth.

Epidemiology forecast

Oral candidiasis is one of the most common fungal infection of the mouth and represents the most common opportunistic for oral infection in humans. Infections of the mouth occur in about 6% of babies less than a month old. Around 20% of those receiving chemotherapy for cancer and 20% of those with AIDS also develop this infection.

An estimated 20% of women are likely to be asymptomatically colonized by vaginal yeast. In the United States, there are around 1.4 million doctor office visits every year for candidiasis. About three-quarters of the women have at least one yeast infection at some time during their lives.

Oesophagal candidiasis is the most common oesophagal infection in persons with AIDS and accounts for about 50% of all oesophagal infections, often coexisting with other oesophagal diseases. About two-thirds of people with AIDS and oesophagal candidiasis also have oral candidiasis.

Candida is the fourth most common cause of bloodstream infections among hospital patients in the U.S. During 2013-2017; the average incidence was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population. As per the Centers for Disease Control and Prevention (CDC), approximately 25,000 cases of candidemia occur nationwide each year.

The epidemiology forecast of candidiasis is covered for major countries including the U.S., Canada, Japan, U.K., Germany, France, Italy, and Spain. It covers estimated prevalent population and treated patient population for the forecast period 2020-2027 as well.

Pipeline Analysis

As of March 2019, the candidiasis therapeutics pipeline comprised more than 25 drugs in different stages of development.

A number of drug manufacturers are actively involved in the development of candidiasis therapeutics. For instance,

  • Ibrexafungerp (formerly SCY-078): On April 21st 2020, SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral Ibrexafungerp (formerly SCY-078), a novel broad-spectrum antifungal, as a treatment for women with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. With these results, ibrexafungerp has now achieved superiority over placebo with a high degree of statistical significance on key study endpoints required for regulatory approval of the VVC indication in both VANISH pivotal trials, clearing the way for the NDA submission for the treatment of VVC in the second half of 2020.
  • Oteseconazole (VT-1161): In February 2020, Mycovia Pharmaceuticals, Inc. has initiated extension studies as part of its ongoing Phase 3 VIOLET clinical trials for oteseconazole (VT-1161). Mycovia is developing oteseconazole, an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no approved treatment in the U.S.

Hence, with positive clinical trial results and growing adoption of collaboration strategies are enhancing candidiasis therapeutics pipeline.

In addition, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the National Institutes of Health (NIH), the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), among others.

Pricing Analysis:

COVID-19 Impact Analysis

The market for candidiasis therapeutics is expected to grow significantly due to the rising cases of COVID-19 cases globally. There is an increased risk for critically ill COVID-19 patients to develop co-infection with Candida, which is likely to increase mortality rates. Despite the progress in public health and hospital care, infections continue to develop in hospitalised patients with COVID-19. COVID-19 patients in ICU, are at high risk of developing nosocomial infections associated with MV and respiratory manifestation. The main risk factors for invasive candidemia patients include prolonging hospital stays, CVC, surgical procedure and the use of broad-spectrum antibiotics. The high mortality increase the demand for early recognition of candidemia, and appropriate antifungal therapy are basic requirements to improve the outcome of COVID-19 patients in ICU. Hence, with rising demand for treatment of rising cases, there is a significant increase in research & development for the treatment of these infections, hence, expected to boost the market growth over the forecast period.

Segment Analysis

By product type, the candidiasis therapeutics market is classified into oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis.

Vulvovaginal Candidiasis (VVC) segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Vulvovaginal Candidiasis (VVC), also known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis. VVC infections are commonly caused by Candida albicans, fluconazole-resistant Candida strains, such as Candida glabrata. VVC is associated with substantial morbidity, including significant genital discomfort, psychological distress, reduced sexual pleasure, and loss of productivity. Some of the common VVC symptoms include vaginal soreness, pruritus, irritation, abnormal vaginal discharge, and excoriation of the vaginal mucosa. About 70-75% of women globally have at least one episode of vulvovaginal candidiasis in their lifetime, and around 40-50% of them experience two or more episodes. Approximately 6-8% of women with VVC suffer from recurrent disease, defined as experiencing at least three outbreaks within 12 months.

Some of the treatments available for vulvovaginal candidiasis include topical azole antifungals such as miconazole, clotrimazole, others and fluconazole, the only orally-administered antifungal currently approved for the treatment of VVC in the United States. Fluconazole reported a 55% therapeutic cure rate in its label, which now also includes warnings of the potential for fetal harm, illustrating the need for new oral alternatives. The conditions of women with moderate-to-severe VVC, VVC caused by fluconazole-resistant Candida spp, recurrent VVC, and VVC during child-bearing age are not fully treated by oral fluconazole or topical products. Also, there are no oral alternatives for VVC patients who do not respond to or do not tolerate fluconazole, and there are no FDA-approved products for the prevention of recurrent VVC.

On the basis of drug class, the candidiasis therapeutics market is classified into Polyene, Azole Antifungals, Topical azoles, Glucan synthesis inhibitors (echinocandins), Antimetabolite, Allylamines, and others.

Azoles Antifungals are expected to dominate the candidiasis therapeutics market during the forecast period

Azoles Antifungals are synthetic compounds which include two groups, imidazoles and triazoles. Imidazole agents include miconazole, ketoconazole, and clotrimazole. In August 2013, the FDA announced that clinicians should no longer prescribe ketoconazole (Nizoral, Janssen Pharmaceuticals) tablets as first-line therapy for any fungal infection, including Candida and dermatophyte infections, because of the adrenal insufficiency, risk for severe liver injury, and adverse drug interactions. Ketoconazole tablets were also withdrawn from the market in the European Union in July 2013.

Triazole agents are now the most commonly used azoles, include itraconazole, fluconazole,terconazole , butoconazole, econazole, and tioconazole. Recent triazoles ( such as, posaconazole, voriconazole, ravuconazole) are active against fluconazole-resistant strains of Candida. Posaconazole and Voriconazole and have shown high efficacy against candidiasis in recent clinical trials.

  • Fluconazole (Diflucan): This triazole has less effect on human sterol metabolism and does not decrease cortisol and testosterone levels, as occurs with ketoconazole. It has fewer adverse effects and better tissue distribution than older systemic imidazoles. It is available as PO/IV and has demonstrated efficacy in topical and invasive forms of candidiasis.
  • Itraconazole (Sporanox): Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P450-dependent synthesis of ergosterol, a vital component of fungal cell membranes. It is effective against broad range of fungi, including Candida species, and is indicated for treatment of cutaneous, oral, esophageal, and disseminated candidiasis.
  • Voriconazole (Vfend): Effective as fluconazole against esophageal candidiasis, and as effective as amphotericin B deoxycholate in treatment of candidemia and invasive candidiasis. In Europe, it has been approved for "treatment of fluconazole-resistant serious invasive Candida infections (including C krusei)." The FDA has approved this drug for esophageal candidiasis and candidemia.
  • Posaconazole (Noxafil): It blocks ergosterol synthesis of cell membrane by inhibiting enzyme lanosterol 14-alpha-demethylase and sterol precursor accumulation. The action results in cell membrane disruption. It is approved for treatment of OPC, including OPC refractory to itraconazole and/or fluconazole and for prophylaxis of infections due to Candida and Aspergillus in patients who are at high risk.

Geographical Analysis

North America region holds the largest market share global candidiasis therapeutics market

North America region is dominating the global candidiasis therapeutics market accounted for the largest market share in 2019, owing to the large investment in healthcare and growing awareness towards the candidiasis disorder. The candidiasis disease is increasing rapidly in the United States and is not restricted to any particular region. The market for systemic candidiasis is increasing in this region. Candida is one of the major cause of healthcare-associated bloodstream infections in U.S. hospitals. Thrush occurs in around 2-5% of healthy newborns and affects mainly during their first year of life. More than one million adult women and adolescent girls in the United States develop vaginal yeast infections annually. Hence, the high incidence rate of candidiasis is expected to drive the growth of the market in this region.

These infections are also costly for patients and healthcare facilities. Each case of candidemia is estimated to result in an additional 3 to 13 days of hospitalization and $6,000 to $29,000 in healthcare costs.15 Although antifungals can be used to treat most candidemia, some types of Candida are increasingly resistant to the antifungal drugs commonly used for treatment, such as the echinocandins (anidulafungin, caspofungin, and micafungin) and fluconazole.

Competitive Landscape

The candidiasis therapeutics market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Cidara Therapeutics Inc., NovaDigm Therapeutics Inc., Amplyx Pharmaceuticals Inc., Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Merck, SCYNEXIS, Inc., Pacgen Biopharmaceuticals, Viamet Pharmaceuticals Holdings, LLC, Mycovia Pharmaceuticals Inc., Novabiotics Limited, Bayer AG, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the candidiasis therapeutics market globally.

Cidara Therapeutics Inc.

Overview: Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California. It is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. In 2019, Cidara was named a San Diego Metro Area top workplace for the third consecutive year by the San Diego Union-Tribune.

Product Portfolio: The Company's portfolio comprised its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform.

Key Development: In May 20, 2020, Cidara Therapeutics, Inc. announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal candidate, rezafungin. Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.

Mergers and Acquisitions: On July 2020, ANI Pharmaceuticals, Inc. published that they are expected a acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million. The current annual U.S. market for this product is approximately $40 million.

Why Purchase the Report?

  • Visualize the composition of the candidiasis therapeutics market segmentation by type, drug class, route of administration, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in candidiasis therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of candidiasis therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global candidiasis therapeutics market report would provide an access to an approx. 69 market data table, 68 figures and 300 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Candidiasis Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Candidiasis Therapeutics Market - Market Definition and Overview

3. Global Candidiasis Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Drug Class
  • 3.3. Market snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Candidiasis Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing number of patients affected by candidiasis infection
      • 4.1.1.2. Growing awareness towards candidiasis infection
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Availability of alternative treatments
      • 4.1.2.2. Side-effects caused by the drugs
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Candidiasis Therapeutics Market - Industry Analysis

  • 5.1. Epidemiology
  • 5.2. Pipeline Analysis
  • 5.3. Porter's Five Forces Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Clinical Trials
  • 5.6. Pricing Analysis
  • 5.7. Regulatory Analysis
  • 5.8. Reimbursement Analysis
  • 5.9. Unmet Needs

6. Global Candidiasis Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Candidiasis Therapeutics Market - By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Oral Candidiasis*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Vulvovaginal Candidiasis
    • 7.3.3. Cutaneous Candidiasis
    • 7.3.4. Invasive Candidiasis
    • 7.3.5. Systemic Candidiasis

8. Global Candidiasis Therapeutics Market - By Drug Class

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3. Market Attractiveness Index, By Drug Class Segment
    • 8.3.1. Polyene*
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.2. Nystatin (Mycostatin and others)
      • 8.3.1.3. Amphotericin B (Fungizone, Amphocin)
    • 8.3.2. Azole Antifungals
      • 8.3.2.1. Fluconazole (Diflucan)
      • 8.3.2.2. Itraconazole (Sporanox)
      • 8.3.2.3. Voriconazole (Vfend)
      • 8.3.2.4. Posaconazole (Noxafil)
    • 8.3.3. Topical azoles
      • 8.3.3.1. Clotrimazole (Mycelex, Femizole-7)
      • 8.3.3.2. Butoconazole (Femstat-3, Gynazole-1)
      • 8.3.3.3. Miconazole vaginal (Monistat, Micatin)
      • 8.3.3.4. Tioconazole (Vagistat-1)
      • 8.3.3.5. Terconazole vaginal (Terazol-7, Terazol-3)
    • 8.3.4. Glucan synthesis inhibitors (echinocandins)
      • 8.3.4.1. Caspofungin (Cancidas)
      • 8.3.4.2. Micafungin (Mycamine)
      • 8.3.4.3. Anidulafungin (Eraxis)
    • 8.3.5. Antimetabolite
      • 8.3.5.1. Flucytosine (Ancobon)
    • 8.3.6. Allylamines
      • 8.3.6.1. Terbinafine (Daskil, Lamisil)
    • 8.3.7. Others

9. Global Candidiasis Therapeutics Market - By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Parenteral
    • 9.3.3. Topical

10. Global Candidiasis Therapeutics Market - By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Hospital Pharmacies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies
    • 10.3.4. Others

11. Global Candidiasis Therapeutics Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Global Candidiasis Therapeutics Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Candidiasis Therapeutics Market- Company Profiles

  • 13.1. Cidara Therapeutics Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. NovaDigm Therapeutics Inc
  • 13.3. Amplyx Pharmaceuticals Inc.
  • 13.4. Astellas Pharma Inc.
  • 13.5. Basilea Pharmaceutica Ltd.
  • 13.6. Grupo Ferrer Internacional, S.A.
  • 13.7. Pacgen Biopharmaceuticals
  • 13.8. Viamet Pharmaceuticals Holdings, LLC
  • 13.9. Mycovia Pharmaceuticals Inc
  • 13.10. Novabiotics Limited
  • 13.11. Bayer AG
  • 13.12. Biomar Microbial Technologies
  • 13.13. Merck
  • 13.14. Scynexis Inc.
  • 13.15. Pfizer, Inc.

LIST NOT EXHAUSTIVE

14. Global Candidiasis Therapeutics Market - Premium Insights

15. Global Candidiasis Therapeutics Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us